市场调查报告书
商品编码
1451577
2024-2032 年按测试、产品、最终用户和地区分類的临床诊断市场报告Clinical Diagnostics Market Report by Test, Product, End User, and Region 2024-2032 |
2023年全球临床诊断市场规模达到816亿美元。展望未来, IMARC Group预计到2032年市场规模将达到1,438亿美元,2024-2032年复合年增长率(CAGR)为6.4%。自体免疫疾病数量的不断增加、医疗旅游的上升趋势(特别是在拥有先进医疗保健系统的国家)以及对个人化医疗和诊断的日益增长的倾向是推动市场的一些主要因素。
临床诊断是指专注于检测和识别疾病和医疗状况的医学分支。它们使医疗保健专业人员能够透过各种测试、程序和评估准确诊断各种疾病。它们提供可靠且及时的信息,有助于医疗决策。它们还为临床医生提供对于评估患者健康、规划治疗方案以及采用一系列复杂方法进行预后评估至关重要的资料。它们透过支持准确的早期诊断在医疗保健中发挥重要作用,从而促进预防性护理并监测治疗的有效性。
狼疮和类风湿性关节炎等自体免疫疾病的数量不断增加,推动了对专门临床诊断的需求,以便在世界范围内及早发现这些疾病并对其进行有效管理。此外,医疗旅游的上升趋势,特别是在拥有先进医疗保健系统的国家,正在刺激对广泛临床诊断测试的需求。此外,由于慢性病和传染病的盛行率激增,以及人口老化加剧(更容易出现这些疾病),人们越来越倾向于个人化医疗和诊断,这对市场产生了积极影响。除此之外,专业诊断中心数量的增加确保更容易获得检测,这有利于市场的成长。此外,人们越来越喜欢床边检测(POCT),医疗保健提供者可以在床边快速轻鬆地诊断和监测患者,这为市场创造了积极的前景。
生活方式疾病增加
在全球范围内,肥胖、高血压和糖尿病等与生活方式相关的疾病的盛行率呈上升趋势。现今普遍存在的久坐生活方式和不良饮食习惯是导致这些疾病的主要原因。临床诊断在早期发现、促进预防措施和客製化治疗计划方面发挥着至关重要的作用。及时诊断通常可以挽救生命,并可以减轻医疗保健系统的整体负担。因此,生活方式疾病的增加提高了对先进临床诊断技术的需求,以有效管理和控制这些疾病。
医疗保健意识的提高
公众越来越意识到医疗保健和预防措施的重要性,部分原因是透过网路和公共卫生运动获取资讯的机会增加。这种意识的提高导致越来越多的人寻求定期检查和诊断测试作为预防性医疗保健的一部分。这种主动的健康管理极大地推动了对临床诊断的需求,因为个人寻求了解他们的健康指标并儘早发现潜在的问题。
不断增长的政府措施和政策
世界各国政府都在大力投资医疗基础设施,并推行鼓励定期医疗检查的政策。医疗保健补贴、针对早期疾病检测的公共卫生运动以及增加医学研究资金等措施对临床诊断的需求产生直接影响。这些计划使人们更容易获得和负担得起诊断服务,从而提高了利用率。
The global clinical diagnostics market size reached US$ 81.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 143.8 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032. The increasing number of autoimmune disorders, rising trend of medical tourism, particularly in countries with advanced healthcare systems, and the growing inclination towards personalized medicine and diagnostics are some of the major factors propelling the market.
Clinical diagnostics refer to a branch of medicine that focuses on detecting and identifying diseases and medical conditions. They allow healthcare professionals to accurately diagnose a wide range of illnesses through various tests, procedures, and evaluations. They provide reliable and timely information that aids in medical decision making. They also offer clinicians data that is vital for assessing patient health, planning treatment protocols, and making prognostic evaluations by employing a range of sophisticated methodologies. They play an essential role in healthcare by supporting accurate and early diagnoses, which facilitates preventive care and monitors the effectiveness of treatments.
The increasing number of autoimmune disorders like lupus and rheumatoid arthritis are driving the need for specialized clinical diagnostics to detect these conditions early and manage them effectively around the world. Moreover, the rising trend of medical tourism, particularly in countries with advanced healthcare systems, is catalyzing the demand for a wide range of clinical diagnostic tests. In addition, the growing inclination towards personalized medicine and diagnostics on account of the surging prevalence of chronic and infectious diseases and the increasing aging population, which is more prone to develop these medical conditions, is influencing the market positively. Apart from this, the rising number of specialized diagnostic centers ensure easier access to testing, which is favoring the growth of the market. Furthermore, the growing preference for point of care testing (POCT) that allows healthcare providers to diagnose and monitor patients at the point of care quickly and easily is creating a positive outlook for the market.
Increase in lifestyle diseases
The prevalence of lifestyle-related diseases like obesity, hypertension, and diabetes is on the upswing, globally. The sedentary lifestyles and poor dietary habits prevalent today contribute significantly to these conditions. Clinical diagnostics play a crucial role in early detection, facilitating preventive measures and tailored treatment plans. Timely diagnosis can often be lifesaving and can reduce the overall burden on healthcare systems. The rise in lifestyle diseases thereby elevates the need for advanced clinical diagnostics to manage and contain these conditions effectively.
Rise in healthcare awareness
The public is becoming more aware about the importance of healthcare and preventative measures, partly due to increased accessibility to information via the internet and public health campaigns. This increased awareness is leading to a higher rate of people seeking regular check-ups and diagnostic tests as part of preventative healthcare. Such proactive health management significantly drives the demand for clinical diagnostics, as individuals seek to understand their health metrics and catch potential issues early.
Growing government initiatives and policies
Governments worldwide are investing heavily in healthcare infrastructure and promoting policies that encourage regular medical screenings. Initiatives, such as subsidized healthcare, public health campaigns targeting early disease detection, and increased funding for medical research have a direct impact on the demand for clinical diagnostics. These programs make diagnostic services more accessible and affordable for the population, thereby driving up utilization rates.
IMARC Group provides an analysis of the key trends in each segment of the global clinical diagnostics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on test, product, and end user.
Lipid Panel
Liver Panel
Renal Panel
Complete Blood Count
Electrolyte Testing
Infectious Disease Testing
Others
Lipid panel dominates the market
The report has provided a detailed breakup and analysis of the market based on the test. This includes lipid panel, liver panel, renal panel, complete blood count, electrolyte testing, infectious disease testing, and others. According to the report, lipid panel represented the largest segment. A lipid panel is a blood test that measures different types of fats and cholesterol levels in the blood, notably low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. The test provides valuable information about the risk for heart disease of an individual and helps guide decisions about what treatment can be best if there is borderline or high risk.
A liver panel is a group of blood tests that evaluate the function of the liver and check for signs of liver damage or inflammation. The panel can include tests like alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin, among others. These results can aid in diagnosing liver diseases such as hepatitis or cirrhosis, and can also monitor the effects of certain medications on the liver.
The renal panel, also commonly known as a kidney panel, consists of various tests aimed at assessing kidney function. It often includes measurements of elements such as creatinine, blood urea nitrogen (BUN), and electrolytes like sodium, potassium, and chloride. The test is critical for diagnosing kidney diseases and for monitoring individuals who are at risk for kidney complications due to conditions like diabetes or high blood pressure.
Instruments
Reagents
Others
Instruments holds the largest share in the market
A detailed breakup and analysis of the market based on the product has also been provided in the report. This includes instruments, reagents, and others. According to the report, instruments accounted for the largest market share. Instruments in clinical diagnostics refer to the specialized machinery and devices used to carry out various tests. These range from simple equipment like centrifuges, which separate different components of blood, to more complex machines like polymerase chain reaction (PCR) devices, which are used for DNA testing. Other instruments can include hematology analyzers for blood cell counts, biochemistry analyzers for measuring chemical substances in the blood, and imaging devices like X-rays or MRIs. These instruments are designed to be highly accurate and efficient, allowing for quick and reliable diagnoses.
Reagents are the chemical substances or compounds used in conjunction with diagnostic instruments to conduct tests. They interact with the samples of blood, urine, or tissue to produce measurable outcomes. Reagents can include antibodies used in immunoassays, chemical indicators, and enzymes. They are typically produced under strict quality control measures to ensure their efficacy and reliability.
Hospital Laboratory
Diagnostic Laboratory
Point-of-care Testing
Others
Diagnostic laboratory dominates the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospital laboratory, diagnostic laboratory, point-of-care testing, and others. According to the report, diagnostic laboratory represented the largest segment. Diagnostic laboratories are specialized facilities that focus solely on conducting diagnostic tests. They often serve multiple healthcare providers and may even accept samples from across different regions. These labs typically offer a wide array of tests, including specialized ones that a hospital lab might not provide. Diagnostic laboratories are crucial for outpatient care and ongoing monitoring of chronic conditions.
Point-of-care testing (POCT) refers to diagnostic tests that are conducted at or near the site where care is provided, usually by non-laboratory personnel. These tests are often simpler and quicker, designed to provide immediate results that can be acted upon without delay. Examples include glucose monitoring for diabetes patients and rapid strep tests in a primary care setting. POCT is invaluable in situations that require quick decision-making and immediate treatment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest clinical diagnostics market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The increasing awareness about the benefits of clinical diagnostics among the masses represents one of the primary factors bolstering the market growth in the North American region. Moreover, the rising adoption of automation in medical testing is contributing to the market growth in the region. Besides this, the growing utilization of mobile health (m-health) applications is influencing the market positively.
The leading companies are integrating artificial intelligence (AI), machine learning (ML), and the internet of things (IoT) to interpret complex data sets, including medical images like X-rays and MRIs that can identify patterns and anomalies that can be missed by human eyes, thereby increasing the accuracy of diagnoses. They are also using genomic sequencing technologies like next-generation sequencing (NGS) that enable rapid and accurate identification of genetic markers for various diseases, which allows for personalized treatment plans that are more targeted and effective. Moreover, key players are utilizing liquid biopsy that allows for the detection of cancer cells or DNA fragments in the blood, which offers a less invasive alternative to traditional tissue biopsies.
Abbott Laboratories
Becton Dickinson and Company
bioMerieux SA
Bio-Rad Laboratories Inc.
Danaher Corporation
F. Hoffmann-La Roche AG
Qiagen N.V.
Quest Diagnostics Incorporated
Siemens AG
Sysmex Corporation
Thermo Fisher Scientific Inc
In 2022, Qiagen N.V. developed NeuMoDxHSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) with approval from the European Commission.
In 2021, F. Hoffmann-La Roche AG acquired GenMark Diagnostics Inc. to access novel technology and test for pathogens with one patient sample.
In 2023, Abbott Laboratories recently signed a definitive agreement to acquire Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes.